|
|
|
| Influence of different doses of Mifepristone on fibroid sizes in perimenopausal patients with uterine fibroids |
| ZOU Min LIU Yuan-xiang |
| Department of Obstetrics and Gynecology,Traditional Chinese Medicine Hospital of Yichun City in Jiangxi Province, Yichun 336000,China |
|
|
|
|
Abstract Objective To explore the influence of different doses of Mifepristone on the fibroid sizes in perimenopausal patients with uterine fibroids.Methods A total of 60 perimenopausal patients with uterine fibroids treated in our hospital from February 2015 to February 2016 were selected.They were evenly divided into the observation group and the controlgroup in random,30 cases in each group.In the control group,25 mg Mifepristone for oral administration once per day was provided,while in the observation group,half dose of Mifepristone in the control group was used once per day. The course of treatment was lasted for 6 months.The clinical curative effect,the changes of fibroid sizes,the level of estradiol(E2)and progesterone(P),the incidence rate of adverse reactions were compared between the two groups.Results The total clinical effective rate in the observation group was 96.67%,and 90.00%in the control group,there was no significant difference between the two groups(P＞0.05).Compared with before treatment,the sizes of uterus and uterine fibroids after treatment in the two groups were both significantly reduced,with significant differences(P＜0.05).However,there was no significant difference in the sizes of uterus and uterine fibroids after treatment between the two groups (P＞0.05).The total incidence rate of adverse reactions like nausea,vomiting,and profuse sweating was 13.33%, which was lower than that in the control group accounting for 30.00%,with significant difference(P＜0.05).The levels of E2and P after treatment in the two groups was lower than thatbefore treatment,with significantdifferences(P＜0.05).There was no significant difference in the levelof E2and P after treatmentbetween the two groups(P＞0.05).Conclusion Compared with conventional dose,the effect on perimenopausal uterine fibroids treated by low-dose Mifepristone is optimal with a lower incidence of adverse reactions and higher safety,which is worthy of clinical application and promotion.
|
|
|
|
|
|
| [1] |
程雪梅.米非司酮对子宫肌瘤雌、孕激素水平及受体表达的影响[J].贵阳医学院学报，2012，37（4）：419-420.
|
| [2] |
郑九波，李冬华，王亚松，等.子宫肌瘤的发病机制研究进展[J].现代中西医结合杂志，2012，21（29）：3298-3301.
|
| [3] |
郭丽香，工亮，罗跃娥，等.子宫肌瘤并发淀粉样变患者发病机制研究[J].天津医药，2015，16（9）：1006-1008.
|
| [4] |
Buza N，Xu F，Wu W，et al.Recurrent chromosomal aberrations in intravenous leiomyomatosis of the uterus：high-resolution array comparative genomic hybridization study[J]. Hum Pathol，2014，45（9）：1885-1892.
|
| [5] |
尧明凤.米非司酮在子宫肌瘤剔除术后治疗中的疗效观察[J].中国医学工程，2015，23（4）：53-54.
|
| [6] |
秦学玉.子宫肌瘤手术前后应用小剂量米非司酮对手术效果的影响探究[J].中外医学研究，2015，13（5）：41-43.
|
| [7] |
韩丽，马汝平，龙艳，等.小剂量米非司酮联合中药治疗围绝经期子宫肌瘤的临床体会[J].山西医药杂志，2014，43（2）：126-128.
|
| [8] |
孙俊峰，石峰.宫瘤消胶囊联合米非司酮与单用米非司酮治疗子宫肌瘤临床对照研究[J].中国现代医生，2012，50（7）：125-126.
|
| [9] |
臧季贤，季爱华，陈玲玲.患者对子宫肌瘤不同术式的认知调查及分析[J].实用临床医药杂志，2011，15（6）：15-16.
|
| [10] |
江雪娟，陈文华，项旭慧，等.小剂量米非司酮序贯宫瘤消胶囊治疗子宫肌瘤的临床研究[J].海峡药学，2011，23（8）：111-113.
|
| [11] |
李环.宫瘤消胶囊联合米非司酮治疗子宫肌瘤临床观察[J].国际中医中药杂志，2014，36（9）：853-854.
|
| [12] |
Esteve JL，Acosta R，Pérez Y，et al.Treatment of uterine myoma with 5 or 10 mg mifepristone daily during 6 months，post-treatment evolution over 12 months：double-blind randomised clinical trial[J].Eur J Obstet Gvnecol Repmd Biol，2012，161（2）：202-208.
|
| [13] |
Wilson M，Evans F，Mylona E，etal.Microscopic intravenous leiomyomatosis：an incidental finding at myomectomy[J].J Obstet Gynaecol，2010，31（1）：96-97.
|
| [14] |
赵骏达，肖金宝，李燕,等.GnRH-a联合LNG-IUS治疗大子宫腺肌病和子宫肌瘤的疗效观察[J].中国性科学，2016，25（9）：34-37.
|
| [15] |
何慧琴，李晓燕.观察不同剂量米非司酮治疗子宫肌瘤的疗效[J].中国妇幼健康研究，2014，12（5）：826-827，849.
|
| [16] |
朱晓兰，李洁明.米非司酮联合宫瘤消胶囊对子宫肌瘤患者细胞因子和性激素水平影响研究[J].中国性科学，2016，25（4）：56-59.
|
| [17] |
余霞，袁晓燕，犹力，等.不同剂量米非司酮在子宫肌瘤保守治疗中的疗效分析[J].西部医学，2014，26（5）：639-640，643.
|
| [18] |
涂雪松，胡利霞，李枫，等.桂枝茯苓胶囊联合米非司酮治疗子宫肌瘤患者106例临床疗效研究[J].中国性科学，2016，25（10）：42-44.
|
|
|
|
